A compound of formula 1 - wherein R represents hydrogen or C 1-4 alkyl group; R 1 represents a group selected from the group consisting of - wherein R 2 represents hydrogen or C 1-4 alkyl group; R 3 represents hydrogen, halogen, CF 3, CN or C 1-4 alkyl; and R 4 represents hydrogen, halogen or C 1-4 alkyl; a = 0, 1 or 2; b = 0, 1, 2 or 3, c = 1, 2 or 3, and R a, R b, R c and R d represent independently from each other H or C 1-4 alkyl; X represents a C 2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH 2)CH-; Y represents hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy or C 1-4 hydroxyalkyl; Z represents a C 1-4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH 3) or represents a C 2-4 aliphatic hydrocarbon bridge fused with a C 3-6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C 1-4 aliphatic hydrocarbon bridge substituted with a spiro C 3-6 cycloalkyl ring optionally containing one or more double bond; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer. R represents hydrogen or C 1-4 alkyl group; R 1 represents a group selected from the group consisting of - wherein R 2 represents hydrogen or C 1-4 alkyl group; R 3 represents hydrogen, halogen, CF 3, CN or C 1-4 alkyl; and R 4 represents hydrogen, halogen or C 1-4 alkyl; a = 0, 1 or 2; b = 0, 1, 2 or 3, c = 1, 2 or 3, and R a, R b, R c and R d represent independently from each other H or C 1-4 alkyl; X represents a C 2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH 2)CH-; Y represents hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy or C 1-4 hydroxyalkyl; Z represents a C 1-4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH 3) or represents a C 2-4 aliphatic hydrocarbon bridge fused with a C 3-6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C 1-4 aliphatic hydrocarbon bridge substituted with a spiro C 3-6 cycloalkyl ring optionally containing one or more double bond; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer. - wherein R 2 represents hydrogen or C 1-4 alkyl group; R 3 represents hydrogen, halogen, CF 3, CN or C 1-4 alkyl; and R 4 represents hydrogen, halogen or C 1-4 alkyl; a = 0, 1 or 2; b = 0, 1, 2 or 3, c = 1, 2 or 3, and R a, R b, R c and R d represent independently from each other H or C 1-4 alkyl; X represents a C 2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or -CH(CH 2)CH-; Y represents hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy or C 1-4 hydroxyalkyl; Z represents a C 1-4 aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and N(CH 3) or represents a C 2-4 aliphatic hydrocarbon bridge fused with a C 3-6 cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C 1-4 aliphatic hydrocarbon bridge substituted with a spiro C 3-6 cycloalkyl ring optionally containing one or more double bond; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer.